2194 related articles for article (PubMed ID: 17680902)
1. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
[TBL] [Abstract][Full Text] [Related]
2. Lifestyle plus exercise intervention improves metabolic syndrome markers without change in adiponectin in obese girls.
Park TG; Hong HR; Lee J; Kang HS
Ann Nutr Metab; 2007; 51(3):197-203. PubMed ID: 17587789
[TBL] [Abstract][Full Text] [Related]
3. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
4. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
Tang T; Glanville J; Hayden CJ; White D; Barth JH; Balen AH
Hum Reprod; 2006 Jan; 21(1):80-9. PubMed ID: 16199429
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention.
Fu JF; Liang L; Zou CC; Hong F; Wang CL; Wang XM; Zhao ZY
Int J Obes (Lond); 2007 Jan; 31(1):15-22. PubMed ID: 16953257
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metabolic syndrome.
Wagh A; Stone NJ
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
[TBL] [Abstract][Full Text] [Related]
7. Lowering the threshold for defining microalbuminuria: effects of a lifestyle-metformin intervention in obese "normoalbuminuric" non-diabetic subjects.
Cubeddu LX; Alfieri AB; Hoffmann IS
Am J Hypertens; 2008 Jan; 21(1):105-10. PubMed ID: 18091752
[TBL] [Abstract][Full Text] [Related]
8. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
Appel SJ; Harrell JS; Davenport ML
J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
[TBL] [Abstract][Full Text] [Related]
9. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study.
Hoeger KM; Kochman L; Wixom N; Craig K; Miller RK; Guzick DS
Fertil Steril; 2004 Aug; 82(2):421-9. PubMed ID: 15302293
[TBL] [Abstract][Full Text] [Related]
10. Metabolically obese normal weight and phenotypically obese metabolically normal youths: the CASPIAN Study.
Kelishadi R; Cook SR; Motlagh ME; Gouya MM; Ardalan G; Motaghian M; Majdzadeh R; Ramezani MA
J Am Diet Assoc; 2008 Jan; 108(1):82-90. PubMed ID: 18155992
[TBL] [Abstract][Full Text] [Related]
11. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
Andreadis EA; Katsanou PM; Georgiopoulos DX; Tsourous GI; Yfanti GK; Gouveri ET; Diamantopoulos EJ
Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):175-80. PubMed ID: 19053032
[TBL] [Abstract][Full Text] [Related]
12. Higher metabolic syndrome in obese asthmatic compared to obese nonasthmatic adolescent males.
Del-Rio-Navarro BE; Castro-Rodriguez JA; Garibay Nieto N; Berber A; Toussaint G; Sienra-Monge JJ; Romieu I
J Asthma; 2010 Jun; 47(5):501-6. PubMed ID: 20560825
[TBL] [Abstract][Full Text] [Related]
13. Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents.
Caranti DA; de Mello MT; Prado WL; Tock L; Siqueira KO; de Piano A; Lofrano MC; Cristofalo DM; Lederman H; Tufik S; Dâmaso AR
Metabolism; 2007 Sep; 56(9):1293-300. PubMed ID: 17697875
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome and its association with diet and physical activity in US adolescents.
Pan Y; Pratt CA
J Am Diet Assoc; 2008 Feb; 108(2):276-86; discussion 286. PubMed ID: 18237576
[TBL] [Abstract][Full Text] [Related]
15. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
Glueck CJ; Fontaine RN; Wang P; Subbiah MT; Weber K; Illig E; Streicher P; Sieve-Smith L; Tracy TM; Lang JE; McCullough P
Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194
[TBL] [Abstract][Full Text] [Related]
16. Role of metformin for weight management in patients without type 2 diabetes.
Desilets AR; Dhakal-Karki S; Dunican KC
Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
[TBL] [Abstract][Full Text] [Related]
18. The effects of metformin and diet on plasma testosterone and leptin levels in obese men.
Ozata M; Oktenli C; Bingol N; Ozdemir IC
Obes Res; 2001 Nov; 9(11):662-7. PubMed ID: 11707532
[TBL] [Abstract][Full Text] [Related]
19. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors.
St George A; Bauman A; Johnston A; Farrell G; Chey T; George J
J Gastroenterol Hepatol; 2009 Mar; 24(3):399-407. PubMed ID: 19067776
[TBL] [Abstract][Full Text] [Related]
20. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
